IBA - DATA CONCERNING TRANSPARENCY
Louvain-la-Neuve, Belgium, February 12, 2015 - IBA (Ion Beam Applications SA, EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has received today a transparency notification, in accordance with Article 29 §1 al.2 of the Transparency Law (law of May 2, 2007 and Royal Decree of February 14, 2008) and the content of which is summarized below.
During the year 2014, Sopartec SA has sold IBA shares with voting rights, so that as from 12 June 2014, Sopartec SA held 403 049 IBA shares with voting rights. As a result, the sum of the affiliated companies Sopartec SA and Catholic University of Louvain (UCL) has been brought below the 3% threshold provided in Article 34 of IBA's Articles of Association.
| Entity | 31 December 2013 Denominator 27 635 439 | 12 June 2014 Denominator 27 675 955 | ||
| shares with voting rights | % | shares with voting rights | % | |
| Sopartec SA Place de l'Université 1 1348 Louvain-la-Neuve | 529 925 | 1.92% | 403 049 | 1.446% |
| UCL Place de l'Université 1 1348 Louvain-la-Neuve | 426 885 | 1.94% | 426 885 | 1.542% |
| Total | 956 810 | 3.46% | 829 934 | 2.998% |
* * *
*
About IBA
IBA (Ion Beam Applications SA) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.
The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.
IBA employs more than 1,000 people worldwide and is listed on Euronext Brussels, (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB), more information can be found at: www.iba-worldwide.com
For more information, please contact
IBA
Jean-Marc Bothy
Chief Financial Officer
Tel: +32 10 47 58 90
investorrelations@iba-group.com
Thomas Ralet
Vice-President Corporate Communication
Tel : +32 10 47 58 90
communication@iba-group.com
